IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the upcoming 2024 BTIG Virtual Biotechnology Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the upcoming 2024 BTIG Virtual Biotechnology Conference. The event is scheduled for Monday, August 5th, 2024 at 10:00 AM ET.
The conference will feature a fireside chat with Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences, hosted by Justin Zelin, Director of Biotechnology Research Analysis at BTIG. This virtual event provides an opportunity for investors to gain insights into IDEAYA's latest developments in targeted therapeutics for oncology.
A live audio webcast of the conference event will be made available through the conference host, allowing interested parties to tune in remotely.
Details
News Market Reaction – IDYA
The recorded move for IDYA in the trading session of this news was -0.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
2024 BTIG Virtual Biotechnology Conference
Monday, August 5th, 2024 at 10:00 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst
A live audio webcast of the conference event will be available through the conference host.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-august-2024-investor-relations-event-302207926.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.